JPMorgan maintained its Overweight rating on Mankind Pharma Ltd (MANKIND:IN) and increased the price target from INR3,000.00 ...

The funding issue was oversubscribed by 2.7 times and facilitated by InCred, with the company being valued at INR 1,000 crore (around USD 120 million).

Shares of Mankind Pharma plunged nearly 6 percent on January 24, weighed down by a fall in the company's October-December net profit. The company's bottomline dropped over 16 percent on year in Q3 ...

Earnings worries yank Indian shares to third week of losses January 24, 2025 India's Mankind Pharma reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses.

Shares of Mankind Pharma slipped 4 percent to Rs 2,606, snapping its two-day gaining streak on the bourses on January 21 after Macquarie downgraded Mankind Pharma to "Underperform" with a target ...